Log in to save to my catalogue

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of hu...

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of hu...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3b973999c8e94cd6996a2a71167a7056

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau

About this item

Full title

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau

Publisher

England: BioMed Central Ltd

Journal title

Alzheimer's research & therapy, 2019-08, Vol.11 (1), p.67-11, Article 67

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal models of Alzheimer's disease (AD) with initiation at a late disease stage. Thus, we aimed to investigate the effects of interventional late-st...

Alternative Titles

Full title

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_3b973999c8e94cd6996a2a71167a7056

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3b973999c8e94cd6996a2a71167a7056

Other Identifiers

ISSN

1758-9193

E-ISSN

1758-9193

DOI

10.1186/s13195-019-0522-z

How to access this item